Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Advanced hepatocellular carcinoma (HCC) with pulmonary metastasis (PM) has a poor prognosis, and optimal treatment strategies remain controversial. This study compared pulmonary metastasectomy and ...

Given the success of Research Topic <a href=" in Chemotherapy-Resistant Hepatocellular Carcinoma and the rapidly evolving ...

Biopsy showed hepatocellular carcinoma. Management decisions were made. This case was presented at the Harvard Medical School postgraduate course “Primary Care Internal Medicine Principles and ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular ...

Typically, patients treated with systemic therapy for locally advanced hepatocellular carcinoma recur within ... referred to as macrovascular invasion (MVI), is associated with increased risk ...

This is called secondary liver cancer or liver metastases. Hepatocellular carcinoma is also called hepatoma or HCC. It's the most common type of primary liver cancer. Because of this, the information ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...